Business Description
Viking Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92686J1060
Total Employee Number:
65Compare
Compare
Traded in other countries / regions
VKTX.USA0VQA.UK1VT.Germany1VKTX.Italy Index Membership
Russell 1000Russell 3000Russell 2000 IPO Date
2015-04-29Description
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 122.78 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -56.4 | |||||
3-Year EPS without NRI Growth Rate | -52.5 | |||||
3-Year FCF Growth Rate | -57.8 | |||||
3-Year Book Growth Rate | 44.2 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.67 | |||||
9-Day RSI | 48.09 | |||||
14-Day RSI | 47.94 | |||||
3-1 Month Momentum % | 23.7 | |||||
6-1 Month Momentum % | 22.3 | |||||
12-1 Month Momentum % | 47.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.72 | |||||
Quick Ratio | 4.72 | |||||
Cash Ratio | 4.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.6 | |||||
Shareholder Yield % | -0.31 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -87.45 | |||||
ROA % | -78.34 | |||||
ROIC % | -38638.13 | |||||
3-Year ROIIC % | 21179.48 | |||||
ROC (Joel Greenblatt) % | -40427.43 | |||||
ROCE % | -91.43 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 9.53 | |||||
Price-to-Tangible-Book | 9.53 | |||||
EV-to-EBIT | -6.06 | |||||
EV-to-Forward-EBIT | -6.09 | |||||
EV-to-EBITDA | -6.07 | |||||
EV-to-Forward-EBITDA | -6.09 | |||||
EV-to-Forward-Revenue | 37.19 | |||||
EV-to-FCF | -8.11 | |||||
| Price-to-Net-Current-Asset-Value | 9.64 | |||||
| Price-to-Net-Cash | 10.02 | |||||
Earnings Yield (Greenblatt) % | -16.5 | |||||
FCF Yield % | -10.75 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VKTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Viking Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -4.66 | ||
| Beta | 2.6611 | ||
| 3-Year Sharpe Ratio | 0.53 | ||
| 3-Year Sortino Ratio | 1.94 | ||
| Volatility % | 63.32 | ||
| 14-Day RSI | 47.94 | ||
| 14-Day ATR ($) | 1.603036 | ||
| 20-Day SMA ($) | 33.6625 | ||
| 12-1 Month Momentum % | 47.9 | ||
| 52-Week Range ($) | 22.959 - 43.15 | ||
| Shares Outstanding (Mil) | 116.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Viking Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Viking Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-11 16:30 | In 172 days | ||
| Annual report for 2026 | 2027-02-11 | In 171 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-11 | In 171 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-22 16:30 | In 60 days | ||
| Third quarter earnings results for 2026 | 2026-10-22 | In 59 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 16:30 | 33.86 (-2.34%) | ||
| Second quarter earnings results for 2026 | 2026-07-29 | 33.86 (-2.34%) | ||
| William Blair 46th Annual Growth Stock Conference | 2026-06-02 14:00 | 31.27 (-2.46%) | ||
| General meeting for 2026 | 2026-05-19 08:00 | 28.69 (-5.25%) | ||
| Jefferies Global Healthcare Conference | 2026-05-04 13:25 | 30.00 (-4.15%) |
Show
Entries
Viking Therapeutics Inc Frequently Asked Questions
What is Viking Therapeutics Inc(VKTX)'s stock price today?
The current price of VKTX is $33.37. The 52 week high of VKTX is $43.15 and 52 week low is $22.96.
When is next earnings date of Viking Therapeutics Inc(VKTX)?
The next earnings date of Viking Therapeutics Inc(VKTX) is 2026-10-22 Est..
Does Viking Therapeutics Inc(VKTX) pay dividends? If so, how much?
Viking Therapeutics Inc(VKTX) does not pay dividend.
Guru Commentaries on NAS:VKTX
Bumbershootholdings
Bullish
2025 Q4
bumbershoot holdings e28094 letter to partners e28094 2025
What the manager wrote
Viking Therapeutics has been a roller-coaster over the past couple of years, but we remain optimistic as it moves VK2735 into multiple Ph3 trials. This advancement in clinical trials positions Viking favorably within the biopharmaceutical sector, particularly targeting metabolic disorders, which we believe could lead to significant growth opportunities.
Press Release
Articles on Viking Therapeutics Inc
VKTX Positioned for Growth Despite Unprofitability; Guru 13F Data Highlights Mixed Insider Sentiment
18 minutes ago
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers